Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 232
- Registration Number
- NCT06475846
- Locations
- 🇨🇳
Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Comparative Study Between Intravenous Granisetron and Ondansetron on Their Effect on Hemodynamics and Shivering After Spinal Anesthesia in Elective Cesarean Delivery
- Conditions
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 100
- Registration Number
- NCT06437236
- Locations
- 🇪🇬
Sohag university Hospital, Sohag, Egypt
Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Universitas Padjadjaran
- Target Recruit Count
- 38
- Registration Number
- NCT06428084
- Locations
- 🇮🇩
Hasan Sadikin General Hospital, Bandung, West Java, Indonesia
The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- University of Baghdad
- Target Recruit Count
- 250
- Registration Number
- NCT06390787
- Locations
- 🇮🇶
Al-Nassiryah Teaching Hospital, Nasiriyah, Thi Qar, Iraq
Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis Patients
- Conditions
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 92
- Registration Number
- NCT05956899
- Locations
- 🇲🇾
University Malaya, Pantai Valley, Kuala Lumpur, Malaysia
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Immune Oncology Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05872893
- Locations
- 🇦🇲
Hematology Center named after prof. R. Yeolyan, Yerevan, Armenia
A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11)
- Conditions
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 70
- Registration Number
- NCT05755737
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Dexamethasone vs Ondansetron After Cesarean Delivery
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT05692245
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Hopital du Sacre-Coeur de Montreal
- Target Recruit Count
- 10
- Registration Number
- NCT05514483
- Locations
- 🇨🇦
Hôpital Sacré-Coeur de Montréal, Montréal, Quebec, Canada
Examining the Effect of Ondansetron on Bowel Prep Success
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 41
- Registration Number
- NCT05439772
- Locations
- 🇺🇸
SUNY Downstate University Hospital of Brooklyn, Brooklyn, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.